FRAMINGHAM, Mass., and SYDNEY, May 6, 2011 /PRNewswire/ —
HeartWare International, Inc. (NASDAQ:
HTWR – ASX: HIN), a leading innovator of less invasive,
miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today
announced that CEO Doug Godshall is scheduled to make an investor
presentation at the Bank of America Merrill Lynch Health Care
Conference at 10:40 a.m. Pacific Time (1:40 p.m. ET) on Tuesday,
May 10, 2011. The conference is being held May 10-12, 2011 at
the Encore at Wynn in Las Vegas.
A live webcast of the Company’s presentation at the conference
will be available via a link provided at www.heartware.com. An
archived replay of the presentation will also be available shortly
after the presentation time until May 27, 2011.
About HeartWare International
HeartWare International develops and manufactures miniaturized
implantable heart pumps, or ventricular assist devices, to treat
Class IIIB / IV patients suffering from advanced heart failure.
The HeartWare® Ventricular Assist System features the
HVAD® pump, a small full-output circulatory support device (up
to 10L/min flow) designed to be implanted next to the heart,
avoiding the abdominal surgery generally required to implant
competing devices. HeartWare has received CE Marking for the
HeartWare System in the European Union. The device is
currently the subject of United States clinical trials for two
indications: bridge-to-transplant under a continued access protocol
and destination therapy. For additional information, please
visit www.heartware.com.
HeartWare International, Inc. is a member of the Russell
2000® and its securities are publicly traded on The NASDAQ
Stock Market and the Australian Secur
‘/>”/>
